Welcome to our dedicated page for Integra Lifesciences Hldgs Cp SEC filings (Ticker: IART), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integra LifeSciences Holdings Corporation filings document regulatory disclosures for a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Forms 8-K cover operating results and financial condition, including GAAP-to-non-GAAP reconciliations for organic revenue, adjusted EBITDA, adjusted earnings per share, net debt and free cash flow, as well as guidance-related disclosures.
Proxy and material-event filings address board elections, shareholder voting, executive compensation and equity incentive plan amendments. Other filings describe leadership appointments, employment and severance arrangements, and financing matters such as the company’s accounts receivable securitization facility used for liquidity and ongoing business funding.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael J. McBreen, EVP & Chief Commercial Officer, received equity awards as part of his compensation. He was granted 31,909 restricted stock units and a non-qualified stock option for 60,372 shares at an exercise price of $15.67 per share. Both awards vest in three equal annual installments starting on the first anniversary of the grant date, contingent on his continued service. Following the RSU grant, he holds 124,017 shares of common stock directly.
Integra LifeSciences Holdings Corp President and CEO Stuart Essig received significant equity awards as compensation. On 6/1/2026, he was granted 365,297 restricted stock units, each representing one share of common stock, and 705,468 non-qualified stock options with a conversion price of $15.6700 per share.
The option award consists of 482,976 options granted under his employment agreement and 222,492 options granted at the Compensation Committee’s discretion. The RSU award consists of 255,265 RSUs under the employment agreement and 110,032 RSUs granted by the Compensation Committee.
All awards were granted under the company’s equity incentive plan and will vest one-third on the first anniversary of 5/1/2026, then in monthly installments over the following twenty-four months, subject to his continued service. These are grants/awards, not open-market purchases or sales.
Integra LifeSciences Holdings Corp ownership disclosure: Paradigm Capital Management, Inc. reports 4,012,698 shares of Common Stock, representing 5.16% of the class as of 03/31/2026. The filing states these securities are owned by advisory clients and Paradigm has sole voting and dispositive power over these shares.
HILL BARBARA B reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP reported that director Barbara B. Hill received two stock awards of the company’s Common Stock on May 7, 2026. She was granted 17,700 shares and 6,638 shares at a price of $0.00 per share as equity compensation. Following these awards, she directly owns 151,191 shares, and an additional 36,350 shares are held indirectly by a trust.
Integra LifeSciences director Keith Bradley reported routine equity compensation and related tax withholding. He received 17,700 Restricted Stock Units (RSUs) on May 7, 2026 under Integra’s Fifth Amended and Restated 2003 Equity Incentive Plan, with each RSU representing a right to one share of common stock and vesting in full on the one-year anniversary of the grant date. To cover tax obligations, 882 shares of common stock were withheld at $13.92 per share. Following these transactions, Bradley directly holds 88,254 shares of Integra common stock.
Clay Shaundra reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Shaundra Clay received a grant of 17,700 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of IART common stock under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan.
The RSUs vest in full on the one-year anniversary of the May 7, 2026 grant date. Clay elected to defer receipt of the underlying shares, which will be delivered in a single lump sum in the calendar year following the year her service on the Board ends, unless she elected a later year.
GRAVES JEFFREY A reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Jeffrey A. Graves received a grant of 17,700 Restricted Stock Units (RSUs). The award was made on May 7, 2026 under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan, at a grant price of $0.00 per unit.
Each RSU represents a contingent right to receive one share of Integra LifeSciences common stock, so the grant covers 17,700 underlying shares. The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Following this grant, Graves holds 17,700 RSUs directly.
Lo Renee Wonlai reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Renee Wonlai Lo received a grant of 17,700 restricted stock units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one share of IART common stock. The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026, and this award brings her reported RSU holdings to 17,700 units.
SCHADE CHRISTIAN S reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Christian S. Schade received a grant of 17,700 restricted stock units (RSUs) tied to the company’s common stock. The award was made at no cash cost under Integra’s Fifth Amended and Restated 2003 Equity Incentive Plan.
The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Schade elected to defer delivery of the underlying shares until a lump-sum payment is made in the calendar year after his service on the Board ends, or a later year he elected. Following this grant, he holds 17,700 RSUs directly from this award.
Integra LifeSciences Holdings Corporation reported the results of its 2026 Annual Meeting of Stockholders held on May 7, 2026. Stockholders approved Amendment No. 3 to the Fifth Amended and Restated 2003 Equity Incentive Plan, increasing the number of common shares available for equity awards by 3,550,000 shares.
All director nominees were elected, each receiving over 62 million votes in favor, with broker non-votes of 3,918,311 for each nominee. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2026 fiscal year and approved, on an advisory and non-binding basis, the compensation of the named executive officers.